1. Home
  2. COLL vs RZLV Comparison

COLL vs RZLV Comparison

Compare COLL & RZLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • RZLV
  • Stock Information
  • Founded
  • COLL 2002
  • RZLV 2016
  • Country
  • COLL United States
  • RZLV United Kingdom
  • Employees
  • COLL N/A
  • RZLV N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • RZLV
  • Sector
  • COLL Health Care
  • RZLV
  • Exchange
  • COLL Nasdaq
  • RZLV NYSE
  • Market Cap
  • COLL 1.1B
  • RZLV 979.0M
  • IPO Year
  • COLL 2015
  • RZLV N/A
  • Fundamental
  • Price
  • COLL $29.58
  • RZLV $2.73
  • Analyst Decision
  • COLL Strong Buy
  • RZLV
  • Analyst Count
  • COLL 6
  • RZLV 0
  • Target Price
  • COLL $42.00
  • RZLV N/A
  • AVG Volume (30 Days)
  • COLL 440.1K
  • RZLV 96.2K
  • Earning Date
  • COLL 11-07-2024
  • RZLV 11-25-2024
  • Dividend Yield
  • COLL N/A
  • RZLV N/A
  • EPS Growth
  • COLL 757.11
  • RZLV N/A
  • EPS
  • COLL 2.16
  • RZLV N/A
  • Revenue
  • COLL $599,245,000.00
  • RZLV $145,051.00
  • Revenue This Year
  • COLL $13.02
  • RZLV N/A
  • Revenue Next Year
  • COLL $18.01
  • RZLV N/A
  • P/E Ratio
  • COLL $13.68
  • RZLV N/A
  • Revenue Growth
  • COLL 9.62
  • RZLV 25.96
  • 52 Week Low
  • COLL $25.07
  • RZLV $2.60
  • 52 Week High
  • COLL $42.29
  • RZLV $14.50
  • Technical
  • Relative Strength Index (RSI)
  • COLL 26.96
  • RZLV N/A
  • Support Level
  • COLL $29.69
  • RZLV N/A
  • Resistance Level
  • COLL $35.62
  • RZLV N/A
  • Average True Range (ATR)
  • COLL 1.41
  • RZLV 0.00
  • MACD
  • COLL -0.39
  • RZLV 0.00
  • Stochastic Oscillator
  • COLL 6.36
  • RZLV 0.00

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About RZLV REZOLVE AI LTD

Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.

Share on Social Networks: